Abstract
Immune response and inflammation were suggested to play certain roles in the development and complications of type 2 diabetes mellitus. The main objective of this study was to investigate the CD26 expression and its relationship with adenosine deaminase (ADA), dipeptidyl peptidase IV (DPP-IV), γ-glutamyltransferase (GGT), and N-acetyl-β-glucosaminidase (NAG) activities in lymphocytes of type 2 diabetics (T2DM) patients. These parameters were assessed in 25 T2DM patients and 20 control subjects. We observed a decrease in CD26 expression and a significant increase in the ADA activity in T2DM patients when compared with control subjects. There were no differences between activities of DPP-IV, NAG, and GGT in lymphocytes of T2DM patients and control subjects. Meanwhile, a significant negative correlation was observed between CD26 expression and DPP-IV activity in lymphocytes of T2DM patients. Moreover, a positive correlation was found between DPPIV and ADA activities. The results suggest that the reduction of CD26 expression may be associated in the regulation of DPP-IV in T2DM patients.
Similar content being viewed by others
References
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365, 1333–1346.
Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., Halban, P. A., & Ehses, J. A. (2010). Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab, 21, 261–267.
Fernández-Real, J. M., & Pickup, J. C. (2008). Innate immunity, insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism, 19, 10–16.
Stentz, F. B., & Kitabchi, A. E. (2005). Hyperglycemia-induced activation of human T-lymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species. Biochemical and Biophysical Research Communications, 335, 491–495.
Giordano, C., Stassi, G., Todaro, M., De Maria, R., Richiusa, P., Scorsone, A., et al. (1995). Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients. Diabetologia, 38, 953–958.
Greenfield, J. R., & Campbell, L. V. (2006). Relationship between inflammation, insulin resistance and type 2 diabetes: ‘cause or effect’? Current Diabetes Review, 2, 195–211.
Bühling, F., Junker, U., Reinhold, D., Neubert, K., Jäger, L., & Ansorge, S. (1995). Functional role of CD26 on human B lymphocytes. Immunology Letters, 4, 47–51.
Fleischer, B., Sturm, E., De-Vries, J. E., & Spits, H. (1988). Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. Journal of Immunology, 141, 1103–1107.
Dinjens, W. N., ten-Kate, J., van-der-Linden, E. P., Wijnen, J. T., Khan, P. M., & Bosman, F. T. (1989). Distribution of adenosine deaminase complexing protein (ADCP) in human tissues. Journal of Histochemistry and Cytochemistry, 37, 1869–1875.
Mentlein, R. (1999). Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regulatory Peptides, 85, 9–24.
Dong, R. P., Kameoka, J., Hegen, M., Tanaka, T., Xu, Y., Schlossman, S. F., et al. (1996). Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. Journal of Immunology, 156, 1349–1355.
Gorrell, M. D., Gysbers, V., & McCaughan, G. W. (2001). CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scandinavian Journal of Immunology, 54, 249–264.
Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F., & Morimoto, C. (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science, 261, 466–469.
Prakash, M. S., Chennaiah, S., Murthy, Y. S. R., Anjaiah, E., Ananda Rao, S., & Suresh, C. (2006). Altered adenosine deaminase activity in type 2 diabetes mellitus. Journal, Indian Academy of Clinical Medicine, 7, 114–117.
Bopp, A., De Bona, K. S., Bellé, L. P., Moresco, R. N., & Moretto, M. B. (2009). Syzygium cumini inhibits adenosine deaminase activity and reduces glucose levels in hyperglycemic patients. Fundamental and Clinical Pharmacology, 23, 501–507.
Grisk, O., Küster, U., & Ansorge, S. (1993). The activity of gamma-glutamyl transpeptidase (gamma-GT) in populations of mononuclear cells from human peripheral blood. Biological Chemistry Hoppe Seyler, 374, 287–290.
Henson, S. E., Nichols, T. C., Holers, V. M., & Karp, D. R. (1999). The ectoenzyme gamma-glutamyl transpeptidase regulates antiproliferative effects of S-nitrosoglutathione on human T and B lymphocytes. Journal of Immunology, 163, 1845–1852.
André, P., Balkau, B., Born, C., Charles, M. A., Eschwège, E., & D.E.S.I.R. study group. (2006). Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R cohort. Diabetologia, 49, 2599–2603.
Wen, J., Liang, Y., Wang, F., Sun, L., Guo, Y., Duan, X., et al. (2010). C-reactive protein, gamma-glutamyltransferase and type 2 diabetes in a Chinese population. Clin Chim Acta, 411, 198–203.
Campos, P. P., Bakhle, Y. S., & Andrade, S. P. (2008). Mechanisms of wound healing responses in lupus-prone New Zealand White mouse strain. Wound Repair and Regeneration, 16, 416–424.
Reiner, R. G., Tanner, A. R., Keyhani, A. H., & Wright, R. (1981). A comparative study of lysosomal enzyme activity in monocytes and Kupffer cells isolated simultaneously in a rat model of liver injury. Clinical and Experimental Immunology, 43, 376–380.
Böyum, A. (1968). Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scandinavian Journal of Clinical and Laboratory Investigation, 97, 77–89.
Fox, D. A., Hussey, R. E., Fitzgerald, K. A., Acuto, O., Poole, C., Palley, L., et al. (1984). Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. Journal of Immunology, 133, 1250–1256.
Gorrell, M. D., Wickson, J., & McCaughan, G. W. (1991). Expression of the rat CD26 antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes. Cellular Immunology, 134, 205–215.
Wrenger, S., Faust, J., Friedrich, D., Hoffmann, T., Hartig, R., Lendeckel, U., et al. (2006). Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function. Journal of Leukocyte Biology, 80, 621–629.
Giusti, G. (1974). Adenosine deaminase. In H. V. Bergmeyer (Ed.), Methods of enzymatic analysis (pp. 1092–1099). New York: Academic Press.
Schön, E., Demuth, H. U., Barth, A., & Ansorge, S. (1984). Dipeptidyl peptidase IV of human lymphocytes. Evidence for specific hydrolysis of glycylproline p-nitroanilide in T-lymphocytes. Biochemical Journal, 223, 255–258.
Xavier, D. O., Amaral, L. S., Gomes, M. A., Rocha, M. A., Campos, P. R., Cota, B. D., et al. (2010). Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomedicine and Pharmacotherapy, 64, 220–225.
Szasz, G. (1969). Serum cholinesterase. Clinical Chemistry, 15, 124–136.
Bock, O., Kreiselmeyer, I., & Mrowietz, U. (2001). Expression of dipeptidyl-peptidase IV (CD26) on CD8 + T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis. Experimental Dermatology, 10, 414–419.
Wong, P. T., Wong, C. K., Tam, L. S., Li, E. K., Chen, D. P., & Lam, C. W. (2009). Decreased expression of T lymphocyte co-stimulatory molecule CD26 on invariant natural killer T cells in systemic lupus erythematosus. Immunological Investigations, 38, 350–364.
Jeanfavre, D. D., Woska, J. R., Jr., Pargellis, C. A., Kennedy, C. A., Prendergast, J., Stearns, C., et al. (1996). Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Biochemical Pharmacology, 52, 1757–1765.
Tan, E. Y., Mujoomdar, M., & Blay, J. (2004). Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. American Journal of Pathology, 165, 319–330.
Jarmołowska, B., Bielikowicz, K., Iwan, M., Sidor, K., Kostyra, E., & Kaczmarski, M. (2007). Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergy. Peptides, 28, 678–682.
Schmiedl, A., Krainski, J., Schwichtenhövel, F., Schade, J., Klemann, C., & Raber, K. A., et al. (2010). Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory cells and expression of pulmonary surfactant proteins. Clinical and Experimental Allergy, 40, 1794–1808.
Acknowledgments
The authors thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for the grants, Biotécnica (Varginha, MG, Brazil) for providing biochemical reagents, and Eloisa Sporleder (Laboratório de Imunologia of Santa Casa de Misericórdia of Porto Alegre, RS, Brazil). The first author thanks CAPES (Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) for the scholarship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bellé, L.P., Bitencourt, P.E.R., de Bona, K.S. et al. Expression of CD26 and its Association with Dipeptidyl Peptidase IV Activity in Lymphocytes of Type 2 Diabetes Patients. Cell Biochem Biophys 61, 297–302 (2011). https://doi.org/10.1007/s12013-011-9212-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-011-9212-6